I'd like to note that every drug has its sets of side effects, and that the use of GLP-1 agonists in clinical vignettes such as in the case of an obese patient

I'd like to note that every drug has its sets of side effects, and that the use of GLP-1 agonists in clinical vignettes such as in the case of an obese patient with DM are seriously considered. More specifically, pharmacological therapy of obesity is indicated in patients with BMI > 30kg/m^2 or >= 27kg/m^2 [1] with another aggravating condition, such as DM2 or hypertension. [1] Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 100, Issue 2, 1 February 2015, Pages 342–362, https://doi.org/10.1210/jc.2014-3415 https://doi.org/10.1210/jc.2014-3415